Table 2.

Crude and adjusted HRs of all cancers associated with telmisartan use compared with other ARBs

	Events	Person-years	Rate per 1,000/year (95% CI)	Crude HR	Adjusted HR (95% CI)
All cancers
Other ARBs, n (%)	3,712	228,355	16.3 (15.7–16.8)	1.00	1.00 (Reference)
Telmisartan, n (%)	235	15,684	15.0 (13.2–17.0)	0.92	0.93 (0.81–1.06)
Cumulative dose*
≤730 DDD	117	7,543	15.5 (12.9–18.6)	0.97	0.96 (0.80–1.16)
730–1,460 DDD	56	3,889	14.4 (11.1–18.7)	0.89	0.90 (0.69–1.18)
1,460–2,190 DDD	24	1,943	12.4 (8.3–18.4)	0.74	0.78 (0.52–1.17)
>2,190 DDD	38	2,309	16.5 (12.0–22.6)	0.94	0.96 (0.69–1.32)
Cumulative duration*
≤2 years	114	7,952	14.3 (11.9–17.2)	0.90	0.90 (0.75–1.09)
2–4 years	71	4,878	14.6 (11.5–18.4)	0.88	0.89 (0.71–1.13)
4–6 years	34	2,052	16.6 (11.8–23.2)	0.98	1.01 (0.72–1.42)
>6 years	16	802	20.0 (12.2–32.6)	1.06	1.09 (0.66–1.80)

Abbreviations: ARB, angiotensin receptor blocker; CI, confidence interval; DDD, defined daily dose; HR, hazard ratio.

*P for trend >0.05 for both analyses.